USA flag logo/image

An Official Website of the United States Government

A Nanotechnology Enabled Point of Care Diagnostic Platform for Early Stage…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93615
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA143232
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
INANOVATE, INC.
2 Davis Dr RESEARCH TRIANGLE PARK, NC 27709-4627
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: A Nanotechnology Enabled Point of Care Diagnostic Platform for Early Stage Cancer
Agency: HHS
Contract: 1R43CA143232-01A1
Award Amount: $199,156.00
 

Abstract:

DESCRIPTION (provided by applicant): The objective of this proposal is the development, evaluation and validation of a reliable, highly sensitive, point-of-care (P.O.C) diagnostic system, for the early detection and subsequent monitoring of prostate cancer . Of cancers in males, the most common is prostate, with a probability of 1 in 6. Approximately 29% (218,890) of all cancer cases in males are prostate cancer with 27,050 deaths expected. Taking prostate cancer diagnosis to the point-of-care, and incorpora ting a test for a larger, more specific set of biomarkers, onto a low cost disposable platform would significantly increase survival rates and reduce treatment costs. Technological Innovation. This project is innovative in the use of a nano-particle biochi p surface in the context of a protein microarray assay. We aim to exploit the nano-particle attachment approach developed by Inanovate, with the native antigen reverse-capture method developed at Brigham and Women's Hospital (BWH) to obtain very high corre lation rates to prostate cancer. Finally the combination of these two innovations with a real-time read-out enables the test to be performed at point-of-care. Long-Term Goal. The long term goal is to provide a premier platform from which cancer can be dete cted at an early stage and monitored after and during treatment. The first example of this goal will be the launch of a screening test for prostate cancer that will be both sensitive, accurate, and widely available at the point-of-care. Phase I Summary. Th e objective is to demonstrate the feasibility of using a nano-particle based biochip substrate in combination with real-time florescent imaging to measure the concentration of multiple autoantibody biomarkers for early stage detection of prostate cancer. S pecific Aims for Phase I. Aim 1 is to optimize end-point assay performance within the context of the nano- particle biochip substrate. Assay development experiments will be performed with the 28 biomarkers identified at BWH. Aim 2 is to develop a real-time fluorescent detection systems specifically suited for the BWH approach. Aim 3 is to show direct comparisons to the end-point data collected in Aim 1 and the ability to detect previously identified prostate cancer correlation signatures in the real-time mo de. Phase II Objectives. 1) Integrate automated sample preparation and labeling into platform module, and prepare for Device Master Filing (DMF). 2) Streamline supply and incorporation of bait proteins into disposable chip. 3) Finalize biomarker panel vali dation in collaboration with BWH, and design multi-site clinical trial for Pre-Market Approval (PMA). 4) Initiate DMF and PMA with support from partners. Commercial Opportunity. The potential market for P.O.C prostate cancer screening is estimated at over 2B p.a. Furthermore, by helping make accurate cancer screening available and affordable to everyone, we see the underlying diagnostic platform proposed herein playing a key role in moving the health industry's focus away from inefficient late stage treatm ents, towards early stage diagnosis and lower cost therapies. PUBLIC HEALTH RELEVANCE: Treatments are available for most cancers; however, survival rates depend largely on the stage at which the cancer is diagnosed. The problem is related to having an accu rate test, but also related to the cost and widespread availability of such a test. We propose to develop a nanotechnology enabled protein signature based diagnostic test for prostate cancer available at the point of primary care.

Principal Investigator:

James C. Nelson
9193541027
JNELSON@INANOVATE.COM

Business Contact:

David Ure
dure@inanovate.com
Small Business Information at Submission:

INANOVATE, INC.
INANOVATE, INC. 2 Davis Dr RESEARCH TRIANGLE PARK, NC 27709

EIN/Tax ID: 120303246
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No